Home Biosciences is a new breed of biotech, leveraging an asset-centric operating model, designed to maximize efficiency in Biotech creation and scale-up, inspired from US corporations venture-funded biotech models.
Home Biosciences ended day-to-day operations in January 2025 and now focuses on building value for its companies going forward
Five years after launching the first venture builder fully dedicated to bio.tech in Continental Europe, Home Biosciences will now move to non-operating mode and focus on building value for the companies it co-founded.
We have built, in five years, three companies from scratch, One Biosciences SAS co-founded with Céline Vallot and Institut Curie, Sequantrix GmbH co-founded with Rafael Kramann, MD, PhD , Rebekka K. Schneider, MD, PhD, and CEO Michael Rheinnecker and UKAA Achen as well as a great scientific team and Apikal Therapeutics SAS co-founded with Guillaume Canaud of Necker Hospital and Laurent Micouin of CNRS
Thanks to a fantastic group of experts, led by Michel Vellard and the entire Home Biosciences team composed of Guillaume Hagege, Nicolas Doulet, Romain LETOURNEUR, Reine Wang and Deborah JAMES, the vision borne by Magali RICHARD and David Schilansky in 2020 has been put in motion: creating a hub-and-spoke model in Europe enabling the creation of tomorrow’s biotech champions.
A huge thank you to our great shareholders, Redmile Group and Sofinnova Partners, for allowing us to launch this bold initiative, so much needed to jumpstart innovation!
Identify – Build – Grow
We worked with academics and scientists on ground-breaking projects addressing unmet medical needs
We brought together talented, highly skilled execution teams and leverage innovative R&D approaches to maximize project outcomes.
We accelerated the discovery and development path thanks to rigorous processes, while making sure the interests of all parties were aligned
Focus – Execute
We assembled dedicated project teams that are empowered and accountable for day-to-day execution
We oversought execution to ensure that projects move forward on time
We provided funding and operational support to allow full focus of the project teams
One Biosciences is a new breed of Techbio in the molecular profiling space, bringing a “step function” in cancer care. The Company uses single-cell-based proprietary technology, including AI-driven analysis, applied to clinical specimens to create a functional profile of a given patient’s tumor at a given point in time. As such, it has the potential to deconvolute the complex and poorly understood biology often present in advanced cancer.
Sequantrix leverages one of the world’s largest human multi-modal, single-cell datasets in the field of fibrotic diseases to discover and validate novel targets and develop anti-fibrotic drug candidates up to the clinical proof of concept. The Company regroups leading pioneers in fibrosis research, clinical care and computational science to address the large, unmet medical need for antifibrotic therapies.
More to come
David Schilansky – co-founder & non-executive chairman
David is today CEO of Ariceum Therapeutics, a leading RLT company hadquartered in Berlin, Germany
David has more than 20 years of professional experience, mainly in the pharma and biotech industry. From 2011 to 2020, he co-headed DBV Technologies, transforming the company from a French research start-up to a unicorn about to launch a treatment of primary importance in the US. During this period, he led two IPOs on Euronext and Nasdaq, raising more than one billion US dollars in total. David began his career as an investment banker in M&A at Warburg Dillon Read. He also worked at Ipsen, from 2005 to 2011, where he held various roles in finance, including that of Group Chief Financial Officer, before moving to DBVT. David graduated from Paris Dauphine and Imperial College (London).
Dr. Magali Richard – co-founder
Maglai is today HP Community Lead at Alan, the health partner that insures, prevents, and supports daily.
Magali has 15 years of experience in biotech, combining academia and industry. Magali graduated from Ecole Polytechnique and Ecole des Mines de Paris, and holds a PhD in Molecular Biology. From 2009 to 2011 she was a Scientist at Biomarin, pursuing in the rare diseases space and gaining biotech experience in the US. Subsequently, Magali spent 6 years at the Boston Consulting Group, member of the Healthcare practice within the Paris office, working with various large pharma, biotech companies and investors, notably around new value creation models for emerging technologies. She then joined the Executive Committee of DBV Technologies as Chief Strategy Officer between 2016 and 2019, in charge of continuing the transformation from a biotech R&D company into an integrated pharmaceutical company.
Home Biosciences has become a dormant company with no Board of Directors
